Renal Cell Carcinoma

The U.S. Food and Drug Administration (FDA) has approved the angiogenesis blocker axitinib (Inlyta), a twice daily oral drug, as a second-line treatment for patients with advanced renal cell carcinoma.

A 28-year-old, slightly obese Caucasian woman presented with a long-standing history of intermittently painful “bumps” on both shoulders and her upper back. Review of systems disclosed regular but very heavy menstrual periods, often lasting for 7 to 9 days, and chronic constipation.

A 60-year-old woman developed metastatic renal cell carcinoma and was given oral sorafenib. Three weeks after commencing treatment, the patient became febrile without signs of localized infection and rapidly developed a nonpruritic, slightly tender cutaneous eruption.

A 56-year-old man with renal cell carcinoma developed widely metastatic disease post nephrectomy, for which he was receiving cyclic sunitinib therapy (50 mg daily for 4 weeks, followed by a 2-week rest period). Toward the end of his second cycle of therapy, he developed minimally pruritic, bright red erythema and fine scale involving both sides of the scrotum.

This treatment guide covers the incidence, epidemiology, etiology and risk factors, signs and symptoms, screening, diagnosis, pathology, staging, prognosis, and the treatment of pancreatic cancer as well as covering pancreatic cystic neoplasms, pancreatic endocrine tumors (PETs), carcinoid tumors of the GI tract, adrenocortical carcinoma, and pheochromocytoma.

Researchers have identified a novel rare, germline mutation linked to a predisposition for both melanoma and renal cell carcinoma (RCC) that results in a five-fold increased risk of developing melanoma, RCC, or both.

Second Opinion series: The patient is a 43-year-old man who was initially evaluated at an outside institution for unexplained anemia and who was found to have a large right kidney mass.
• Malignant Angiomyolipoma: a Rare Entity With Unusual Biology
• An Approach to the Management of Rare Tumors

A 71-year-old, previously healthy male, presents for evaluation of a new, solitary, painless, pedunculated bump on his chin. Past medical history is negative for surgery or transfusion, and he denies intravenous drug use. His review of systems is negative with the exception of complaints about mild right-sided postero-lateral flank pain.

A retrospective study of metastatic renal cell carcinoma (mRCC) patients published in the journal Cancer found that patients treated with tyrosine kinase inhibitors (TKIs) had better overall survival and reduced frequency their cancer metastasizing to the brain.

A 15-year-old male, who carries the diagnosis of von Hipple-Lindau Syndrome, has been followed routinely with CT scans. A mass was subsequently found in the left kidney and the following image was viewed.